The Latest Cardiac and Vascular News
Record Quarterly Revenue of $24.0 Million in Q3 2020, up 172% Year over Year and up 39% from Q2 2020 Adjusted EBITDA Positive in last 2 months of Q3. Expect to be Significantly Adjusted EBITDA positive in 2021 Revenue Growth in 2021 expected in excess of 100% Raised $48.9 million, […]
Worldwide revenue of $54.8 million – a decrease of 3.3% year over year U.S. revenue of $44.7 million – a decrease of 3.1% year over year International revenue of $10.1 million – a decrease of 4.1% year over year MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for […]
Reports Third Quarter Revenues of $10.5 Billion Posts GAAP EPS of $0.82 and Non-GAAP EPS of $1.63 Extends and Strengthens Leading Cardiovascular Franchise with Planned MyoKardia Acquisition Delivers Significant Pipeline and Regulatory Milestones Achieves Positive Results from POETYK-PSO-1 Evaluating Deucravacitinib (TYK2 inhibitor) for the Treatment of Moderate to Severe Plaque […]
Conference Call Scheduled for Today, November 4, 2020, at 3:30 PM CT (4:30 PM ET) Revenues of $60.5 million increased 42% sequentially and decreased 6.1% compared to last year Net loss was $2.1 million, or $0.05 per basic and diluted share Management provides fiscal 2021 second quarter revenue guidance of […]
Topline Results From GALACTIC-HF Show Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events; Trial Did Not Meet Secondary Endpoint of Reduction in Cardiovascular Death Primary results from GALACTIC-HF to be presented as Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions 2020 on November 13, 2020 Enrollment Completed in […]
Total Revenue Increased 39% in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared to Same Periods of 2019 Despite COVID-19 Headwinds Progress Continues Towards VASCEPA® (icosapent ethyl) Approval and Commercialization in Europe Management to Host Conference Call Today at 7:30 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the […]
2020 Q3 HIGHLIGHTS compared to Q2 2020: – Revenues were $10,727,000, an increase of $4,354,000, or 68%, compared to $6,373,000 – Pre-tax net income of $5,595,000, an increase of $4,605,000, or 465%, compared to $990,000 – Net income was $4,866,000, or $0.74 per basic share and $0.61 per diluted share, […]
Tenapanor NDA Accepted for Review by FDA; PDUFA Goal Date set for April 29, 2021 Maintains strong balance sheet with $185.5 million in cash, cash equivalents and short-term investments FREMONT, Calif., Nov. 5, 2020 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for […]
– Fiscal fourth quarter revenues of $4.784 billion grew 4.4% on a reported and currency-neutral basis. – BD’s COVID-19 testing sales totaled more than $440 million in the fourth fiscal quarter. – Fiscal fourth quarter GAAP EPS were $0.36. Non-GAAP EPS were $2.79. FRANKLIN LAKES, N.J., Nov. 5, 2020 /PRNewswire/ — […]
NEW YORK & BRISBANE, Calif.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb’s previously announced tender offer to acquire all outstanding shares of […]
